<span style="margin-left: 0em;">chemotherapy</span> <span style="margin-left: 1em;">Standard of Care (SoC) <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 0em;">immune chekpoint inhibitors</span> <span style="margin-left: 1em;">anti-PD-(L)1</span> <span style="margin-left: 2em;">atezolizumab based treatment</span> <span style="margin-left: 3em;">atezolizumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 2em;">pembrolizumab based treatment</span> <span style="margin-left: 3em;">pembrolizumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
deaths (OS) (5) progression or deaths (PFS) (5) objective responses (ORR) (5) DOR (5) deaths (OS) (extension) (4) objective responses (ORR) (extension) (2) DOR (extension) (1) PFS (extension) (1) AE (any grade) (3) TRAE (any grade) (3) AE leading to treatment discontinuation (any grade) (3) TRAE (grade 3-4) (3) AE (grade 3-4) (3) TRAE leading to death (grade 5) (3) TRAE leading to discontinuation (any grade) (3) AE leading to death (grade 5) (3) SAE (any grade) (2) STRAE (any grade) (2) AE leading to treatment discontinuation (grade 3-4) (1) Anaemia TRAE (grade 3-4) (3) Neutropenia TRAE (grade 3-4) (3) Fatigue TRAE (grade 3-4) (3) Peripheral neuropathy TRAE (grade 3-4) (3) Constipation TRAE (grade 3-4) (3) Asthenia TRAE (grade 3-4) (3) Febrile neutropenia TRAE (grade 3-4) (2) Nausea TRAE (grade 3-4) (1) Decreased appetite TRAE (grade 3-4) (1) Pruritus TRAE (grade 3-4) (1) Diarrhoea TRAE (grade 3-4) (1) Colitis TRAE (grade 3-4) (1) Hyperthyroidism TRAE (grade 3-4) (1) Thyroiditis TRAE (grade 3-4) (1) Alopecia TRAE (grade 3-4) (1) Adrenal insufficiency TRAE (grade 3-4) (1) Severe skin reaction TRAE (grade 3-4) (1) Nephritis TRAE (grade 3-4) (1) Myositis TRAE (grade 3-4) (1) Infusion-related reactions TRAE (grade 3-4) (1) Pneumonitis TRAE (grade 3-4) (1) Fatigue AE (grade 3-4) (1) Asthenia AE (grade 3-4) (1) Headache AE (grade 3-4) (1) Decreased appetite AE (grade 3-4) (1) Cough AE (grade 3-4) (1) Dyspnoea AE (grade 3-4) (1) Diarrhoea AE (grade 3-4) (1) Rash AE (grade 3-4) (1) Increased ALT AE (grade 3-4) (1) Increase AST AE (grade 3-4) (1) Pyrexia AE (grade 3-4) (1) Weight decreased AE (grade 3-4) (1) Pruritus AE (grade 3-4) (1) Nausea AE (grade 3-4) (1) Vomiting AE (grade 3-4) (1) Back pain AE (grade 3-4) (1) Hypothyroidism AE (grade 3-4) (1) Arthralgia AE (grade 3-4) (1) Stomatitis AE (grade 3-4) (1) Mucosal inflammation AE (grade 3-4) (1) Blood creatinine increased AE (grade 3-4) (1) Dysgeusia AE (grade 3-4) (1) Anaemia AE (grade 3-4) (1) Neutropenia AE (grade 3-4) (1) Dizziness AE (grade 3-4) (1) Dry skin AE (grade 3-4) (1) Peripheral oedema AE (grade 3-4) (1) Constipation AE (grade 3-4) (1) Febrile neutropenia AE (grade 3-4) (1) Blood and lymphatic system disorders AE (grade 3-4) (1) Gastrointestinal disorders AE (grade 3-4) (1) General disorders and administration site conditions AE (grade 3-4) (1) Metabolism and nutrition disorders AE (grade 3-4) (1) Nervous system disorders AE (grade 3-4) (1) Renal and urinary disorders AE (grade 3-4) (1) Acute kidney injury AE (grade 3-4) (1) Respiratory, thoracic and mediastinal disorders AE (grade 3-4) (1) Skin and subcutaneous tissue disorders AE (grade 3-4) (1) Vascular disorders AE (grade 3-4) (1) Abdominal pain AE (grade 3-4) (1) Peripheral neuropathy AE (grade 3-4) (1) Myalgia AE (grade 3-4) (1) Alopecia AE (grade 3-4) (1) Injury, poisoning and procedure AE (grade 3-4) (1) Cardiac disorders AE (grade 3-4) (1) Endocrine disorders AE (grade 3-4) (1) Eye disorders AE (grade 3-4) (1) Infections and infestations AE (grade 3-4) (1) Investigations AE (grade 3-4) (1) Musculoskeletal and connective tissue disorders AE (grade 3-4) (1)
Network meta-analysis for deaths_(OS)
Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence
of assessment of transitivity assumption plausibility. Calculations by netmeta package.
Evidence network for deaths_(OS)
2 KEYNOTE-045 (all population), 2017
KEYNOTE-045 (PDL1 CPS >10%), 2017 3 IMvigor-211 (PDL1>5%), 2018
IMvigor-211 (PDL1>1%), 2018
IMvigor-211 (all population), 2018 atezolizumab alone vs. pembrolizumab alone
1.24 [0.99; 1.55] 1.24 [0.99;1.55]atezolizumab alone vs. pembrolizumab alone
1.24 [0.99; 1.55] atezolizumab alone vs. Standard of Care (SoC)
atezolizumab alone better
0.86 [0.77; 0.96] 0.86 [0.77;0.96]atezolizumab alone vs. Standard of Care (SoC)
atezolizumab alone better
0.86 [0.77; 0.96] pembrolizumab alone vs. atezolizumab alone
0.81 [0.65; 1.01] 0.81 [0.65;1.01]pembrolizumab alone vs. atezolizumab alone
0.81 [0.65; 1.01] pembrolizumab alone vs. Standard of Care (SoC)
pembrolizumab alone better
0.69 [0.57; 0.84] 0.69 [0.57;0.84]pembrolizumab alone vs. Standard of Care (SoC)
pembrolizumab alone better
0.69 [0.57; 0.84] Standard of Care (SoC) vs. atezolizumab alone
atezolizumab alone better
1.16 [1.04; 1.30] 1.16 [1.04;1.30]Standard of Care (SoC) vs. atezolizumab alone
atezolizumab alone better
1.16 [1.04; 1.30] Standard of Care (SoC) vs. pembrolizumab alone
pembrolizumab alone better
1.44 [1.19; 1.75] 1.44 [1.19;1.75]Standard of Care (SoC) vs. pembrolizumab alone
pembrolizumab alone better
1.44 [1.19; 1.75] Standard of Care (SoC) pembrolizumab alone atezolizumab alone direct evidence network meta-analysis comet plot result box odds ratio A B 0.5 1.5 1.0 odds ratio for A vs. B and half 95% CI
T vs. C Standard of Care (SoC) pembrolizumab alone atezolizumab alone Standard of Care (SoC) --- 1.44 1.19; 1.751.16 1.04; 1.30pembrolizumab alone 0.69 0.57; 0.84--- 0.81 0.65; 1.01atezolizumab alone 0.86 0.77; 0.961.24 0.99; 1.55---
pathologies: 290,155,154
- treatments: 361
result logic